CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Jun

Today In Oncology

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Implanted Cesium-131 Tiles Improve Local Control and Survival in Patients With Resected Brain Metastases

Oral Metronomic Chemotherapy Plus Ultra-Low-Dose Immunotherapy Improves Survival in Advanced Head and Neck Cancer

Sacituzumab Govitecan With Pembrolizumab Extends PFS2 in PD-L1–Positive Metastatic Triple-Negative Breast Cancer

Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial

Combining Targeted Immunotherapies With Standard R-CHOP Delays Progression of Aggressive B-Cell Lymphomas